Following the approval of the SGLT-2 inhibitor, dapagliflozin, for CKD treatment, 1,659 and 1,760 patients with CKD initiated treatment with dapagliflozin and/or RAS inhibitors, respectively (Table S3). This evidence concerns the gene SLC5A2 and chronic kidney disease.